Evidence. Protocol. Truth.

Physician-curated deep dives into the science of men's health optimization.

Methylene Blue (Oral) — The Real Drug, the Small Cognitive Signal, and the Serotonin Syndrome Warning No One Mentions

Methylene blue for oral use is a real drug, not a benign supplement. One small acute imaging study (Rodriguez 2016, n=26, 2 mg/kg) drives the cognitive claim. The Alzheimer's tau story is about a different molecule (LMTX). Serotonin syndrome risk with SSRIs, SNRIs, MAOIs is FDA-warned.

23 Jul 2026

Boron — The Trace Mineral, the Small Study, and What It Actually Earns in a Men's Stack

Boron for men's health — the entire optimization case rests on one small pre-post study in eight men (Naghii 2011). No proper RCT replication exists. Safety margin at 3–10 mg/day is generous (adult UL 20 mg/day). Defensible as a low-cost hedge; not a testosterone move.

23 Jul 2026

Monograph

Full-Body MRI Screening — Prenuvo, Ezra, Q Bio, and the Incidentaloma Problem

Per 1,000 asymptomatic adults screened with WB-MRI: ~950 abnormal findings, ~15-20 cancers, ~30% trigger workup. Zero RCT mortality evidence. ACR does not recommend for average-risk adults. Vanguard's read on Prenuvo, Ezra, Q Bio.

19 Jul 2026

Monograph

Galleri — The Multi-Cancer Early Detection Blood Test, and What the 2026 Data Actually Shows

The NHS-Galleri trial missed its primary endpoint at ASCO 2026. High specificity (~99.6%) and PPV (52-62%), modest sensitivity (~30-40% all cancers), zero mortality data. $949 cash pay. No FDA approval as screening. Vanguard's read on the largest multi-cancer detection trial to date.

19 Jul 2026

Monograph

Lab Testing for Men — The Optimization List and the Vanguard List

Two lists — the Optimization List (12 non-negotiable tests before starting hormone, cardiovascular, or metabolic optimization) and the Vanguard List (25 total tests including 13 deep-dive add-ons). Tiered by evidence, honestly.

19 Jul 2026

Monograph

Tadalafil — The Daily PDE5 Inhibitor, and the Longevity Story It's Been Given

07 Jul 2026

Monograph

Losartan — The Uricosuric ARB with a Marfan and TGF-β Story

Losartan (Cozaar, first FDA-approved 1995) is the prototype angiotensin II receptor blocker. It shares the class-level mechanism (selective AT1 receptor blockade), core indications (hypertension, diabetic nephropathy, heart failure, cardiovascular…

05 Jul 2026

Monograph

Fish Oil: The Right Molecule, the Wrong Dose

The short version "Fish oil for your heart" is largely oversold, because the capsule in most cabinets is

30 Jun 2026

Monograph

Glucosamine and Chondroitin — The Honest 2026 Read

Glucosamine and chondroitin sulfate are naturally occurring compounds found in healthy cartilage. Glucosamine is an amino sugar used by the body in glycosaminoglycan and proteoglycan synthesis; chondroitin sulfate is a long-chain sulfated…

23 Jun 2026

Monograph

Cartalax — Khavinson Short-Peptide Bioregulator for Cartilage

Cartalax (Ala-Glu-Asp, AED tripeptide) is one of approximately fifteen short-peptide bioregulators developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. The Khavinson…

12 Jun 2026

Protocol

Mid-Life Cognitive Optimization — A Sober Protocol

30 May 2026

Protocol

Recovery and Training Stack — A Performance Optimization Protocol

30 May 2026

V
Vanguard AI
Research Assistant
Feedback